OCTOBER MARKS THIRD EAHN™ COHORT SELECTION TO COMMERCIALIZE INNOVATIVE TECHNOLOGIES
September 29, 2021 – TORONTO, ON – The Ontario Bioscience Innovation Organization (OBIO®), a not-for-profit organization dedicated to advancing health technology innovation and commercialization, is proud to announce the growth and expansion of its Early Adopter Health Network (EAHN™) partnerships, together with the upcoming selection round of its new cohort.
With more than 18 healthcare members and 11 innovation organization partners from across Canada, the EAHN™ has grown into Canada’s premier health science market acceleration program since its launch in early 2020. Now, OBIO® will be hosting its third cohort network day in October, where innovative companies will meet with healthcare organizations prior to launching new EAHN™ projects later this year.
“We are delighted to expand the EAHN™ with the engagement of so many leading healthcare organizations and with the support of our innovation organization partners,” said Gail Garland, President & CEO of OBIO®. “Growing and maintaining a robust and globally competitive domestic health science industry ecosystem here in Canada requires partnerships and collaborations to get the job done.”
Through the EAHN™, which is supported by the Federal Economic Development Agency of Southern Ontario, OBIO® provides project management and financial support to evaluate technologies in the real-world setting and facilitate their broad adoption into the health system. They connect leading-edge, scaling health science companies with healthcare organizations, providing an opportunity for innovators to access local markets before expanding globally, as well as a strong reason to anchor themselves in Canada.
Driven by OBIO’s unique capacity to pair commercial-ready technologies with clinical end-users who want to deliver improved care at any health institution, the goal for the EAHN™ is to become early adopters of homegrown medical technology and help streamline the procurement process. Through a collaborative and comprehensive approach, EAHN™ addresses both the “push” and “pull” factors of what industry has developed and what burdened hospitals are trying to address. This allows the EAHN™ to catalyze change by delivering improved patient care more efficiently while opening the door to a new health-care economy that benefits Canadians and Canadian companies alike.
OBIO® would like to thank and recognize the following organizations for their involvement and support in the EAHN™:
EAHN™ Healthcare Members:
Baycrest
Bruyère
Centre for Addiction and Mental Health (CAMH)
Hamilton Health Sciences
Health Sciences North
Hôtel-Dieu Grace Healthcare
Joseph Brant Hospital
Kingston Health Sciences Centre
Michael Garron Hospital
North York General Hospital
Southlake Regional Health Centre
St. Mary’s General Hospital
The Ottawa Hospital
Unity Health Toronto
University Health Network (UHN)
West Park Healthcare Centre
Winchester District Memorial Hospital
Women’s College Hospital
EAHN™ Innovation Organization Partners:
Carleton University
Clinical Trials Ontario
Invest Ottawa
Life Sciences British Columbia
Montréal InVivo
Ontario Institute for Regenerative Medicine
Ryerson Biomedical Zone
SOSCIP Consortium
StarFish Medical
Stem Cell Network
Synapse Life Science Consortium
For more information about OBIO’s EAHN™, or if you are interested in being part of the network, please contact Dr. Jeff Aramini at jeffaramini@obio.ca.
About OBIO®
OBIO®, founded in 2009, is a not-for-profit, membership-based innovation organization engaged in strategy, programming, policy development and advocacy to further the commercialization of human health technologies positioning Canada as a leader in the international marketplace. OBIO® advances this goal through collaborative partnerships with industry, the investment community, academia, the health system and government.
For media inquiries, please contact:
Bojana Duric, BlueSky Communications
bduric@blueskycommunications.com
289.981.7710